QRxPharma's opioid greater than the sum of its parts
31 March, 2004 by Renate KrelleMinimising the side-effects that plague patients taking opioid pain-relievers will be the big advantage of Queensland-based QRxPharma’s novel opioid candidate Q8003, according to Alex Baker, Program Manager at QRxPharma.
Southpoint acquires Boron molecular
30 March, 2004 by Melissa TrudingerFormer Perth-based telecommunications company Southpointe (ASX: SOU) plans to become a biotechnology investment company after acquiring interests in two biotechnology-related ventures.
VRI to raise $2.9 million
30 March, 2004 by Melissa TrudingerVRI Biomedical has announced plans to raise up to AUD$2.9 million through a just completed share placement and a non-renounceable rights issue to be put towards production and marketing of the company's proTract probiotic products.
Gradipore changes name to Life Therapeutics
30 March, 2004 by Melissa TrudingerGradipore (ASX: GDP) has changed its name to Life Therapeutics to reflect its new strategy, the company announced today.
Ballard wins Clunies Ross award
29 March, 2004 by Melissa TrudingerSouth Australian biotechnologist Dr John Ballard has been awarded an ATSE Clunies Ross Award in recognition of his achievements in biochemical drug development over the course of his career, which has included starting three biotechnology companies, and more recently an investment organisation, BioAngels.
China OKs Brazil GMO soybean imports
26 March, 2004 by Staff WritersChina approved the importation of genetically modified soybeans from Brazil, which should allow shipments to begin as early as Tuesday for the world's largest soybean importer, according to Brazil's Agriculture Ministry.
Cogstate licences angiotensin compounds for Alzheimers
26 March, 2004 by Melissa TrudingerRecently listed company CogState (ASX: CGS) has signed a licensing and research collaboration deal with Pacific Northwest Biotechnology (PNB) in the US to develop a drug to treat Alzheimer's disease.
Allergan files INDs for Peplin's topical treatment
25 March, 2004 by Renate KrellePeplin Biotech (ASX: PEP) today announced the filing of three separate Investigational New Drug (IND) applications with the US Food and Drug Administration for a topical formulation of its lead compound PEP005.
Select Vaccines signs agreement to develop Hep C test
25 March, 2004 by Melissa TrudingerSelect Vaccines (ASX: SLT) has signed a materials transfer agreement (MTA) with a multinational biotechnology company to access materials it will use to accelerate the development of its hepatitis C rapid diagnostic test.
Prana appoints US analyst to board
25 March, 2004 by Melissa TrudingerMelbourne biotech company Prana Biotechnology (ASX: PBT) has appointed leading US biotech analyst Dr Jonas Alsenas to its board of directors.
Bracks bans GMHT canola until 2008
25 March, 2004 by Graeme O'NeillThe Victorian Government has announced a four-year, legislated moratorium on commercial cropping of genetically modified herbicide-tolerant (GMHT) canola.
Biota signs new flu diagnostic agreement
24 March, 2004 by Melissa TrudingerBiota (ASX:BTA) has signed a new agreement with its US-based flu diagnostics partner Thermo Electron giving it a profit share in a second influenza diagnostic kit, FLU OIA A/B.
GM banned in WA
23 March, 2004 by Iain ScottWestern Australian premier Geoff Gallop has announced that genetically modified food crops will not be grown in the state.
Psivida subsidiary signs manufacturing deal
23 March, 2004 by Melissa TrudingerPsiMedica, the UK subsidiary of Perth-based nanotechnology company Psivida (ASX:PSD), has signed a three-year manufacturing agreement with nuclear pharmaceuticals company Auriga Medical as it gears up to start Phase II clinical trials of its BioSilicon-based brachytherapy product in Singapore later this year.
Axon accepts takeover bid
23 March, 2004 by Renate KrelleMicroarray and cellular screening company Axon Instruments (ASX:AXN) has accepted a friendly takeover offer from California-based Molecular Diagnostics.
